Media Contact media@waterstreet.com

June 112020

Water Street Completes Investment in Solvias

Chicago — Water Street Healthcare Partners announced today that it has completed an agreement to fully acquire and invest in growing Solvias, a world leader in contract research, development and manufacturing. The agreement is the next step in Solvias’ expansion focused on building the company into a global leader of high-quality pharmaceutical laboratory services.

Solvias will engage Water Street's industry expertise and network of resources to extend the company’s capabilities into new and complementary areas and expand its global reach. Water Street also helped Solvias recruit two seasoned pharmaceutical services executives to its board of directors. Solvias has appointed Michael J. Lehmann and Mario L. Rocci, Jr., PhD to join Karen J. Huebscher, PhD, chief executive officer and director of Solvias, on the company’s board:

  • Michael J. Lehmann, chairman, is the former chief commercial officer and president of global pharmaceutical development services for Patheon N.V., where he was instrumental in Patheon’s transformation to a high-growth contract development and manufacturing organization. Mr. Lehmann also spearheaded global early development for Covance Inc. Most recently, he served on the board of BioAgilytix Labs.
  • Mario L. Rocci Jr., director, has more than 30 years of leadership experience in the pharmaceutical services industry and is the former president of ICON plc’s early phase clinical, laboratory, and scientific services division. Dr. Rocci also served as chairman of the Product Quality Research Institute and president of the American Association of Pharmaceutical Scientists.

“We’re thrilled to be growing Solvias in partnership with our new investors and board,” said Dr. Huebscher. “Since Solvias’ founding, we have continuously innovated and expanded our platform of testing, specialized pharmaceutical manufacturing products, analytical kits and services to offer our customers the highest level of scientific expertise and technical capabilities. These newest initiatives support our goal of bringing greater value to our customers and positioning Solvias at the forefront of our industry.”

Founded in 1999, Solvias has grown to serve more than 600 biotech, medical device, cosmetic and top multinational pharmaceutical companies. In recent years, the company has extended its testing and analytical services to address biopharmaceutical products and emerging cell and gene therapies. Solvias has remained fully operational during the current pandemic crisis, providing critical services to customers, including supporting their work to develop therapeutic options and vaccine candidates for COVID-19.

“Solvias is highly regarded for its outstanding quality of work, scientific expertise and commitment to continuous innovation. Its work is critical to supporting organizations with bringing important, life-saving products to market. I’m honored to work with Karen and her team to support their goal of building Solvias into a global industry leader,” said Mr. Lehmann.

About Solvias AG

Solvias is a world leader in contract research, development and manufacturing. The industries the company serves include pharmaceuticals, biotech, medical device and cosmetics. Headquartered near Basel, Switzerland, Solvias employs more than 550 highly qualified team members who work together to understand their customers' needs. Solvias takes pride in delivering innovative solutions that meet the highest quality standards. With its excellent infrastructure and unrivalled expertise, Solvias develops, analyzes and tests a wide range of biological and chemical substances and products. The company also offers one of the largest proprietary ligand portfolios for catalytic transformations and a suite of related custom synthesis and catalysis technology services. Drawing on the company’s well-established scientific experience and proven track record, Solvias provides integrated services, products and technologies to help its customers bring safer and better products to market faster.

Subscribe to Water Street News

To receive Water Street news via email,
please complete the form below.

Privacy Policy

You’ve just been sent an email to confirm your email address. Please click on the link in the email to activate your subscription.

If you do not receive an email from us within a few minutes, please check your spam folder. If our email did not come through to you, please click on this link, news@waterstreet.com